Allen Seylani: Impact of a Treat-to-Target Urate-Lowering Strategy on Cardiovascular Events
Allen Seylani, Scientific Reviewer at Oxford University Press, Resident Physician at Cleveland Clinic, shared a post on LinkedIn about a recent article by Pascal Richette et al. published in JAMA Internal Medicine:
“A new study in JAMA Internal Medicine followed over 100,000 patients with gout and asked a simple but powerful question.
Does treating to a serum urate target below 6 mg/dL actually change cardiovascular outcomes.
The answer appears to be yes.
Patients who achieved target urate levels had a significantly lower risk of major cardiovascular events within 5 years compared with those who did not.
Fewer flares were expected. Fewer heart attacks and strokes were not.
This matters because it reframes gout from a nuisance disease to a systemic inflammatory condition with real cardiovascular consequences. It also challenges us as clinicians and researchers to stop thinking of urate lowering as a checkbox and start thinking of it as disease modification.
The most striking part to me is not just the association, but the implication. Inflammation, not urate alone, may be the missing link connecting gout to cardiovascular risk. Treating to target likely works because it quiets chronic inflammation, reduces flare related inflammatory surges, and stabilizes the system as a whole.
And yet, fewer than one third of patients actually reached target urate levels within a year.
That gap between evidence and practice is where leadership lives.
This is where better care models, tighter follow up, patient education, and accountability can change outcomes at scale. It is also where translational thinking matters, connecting population data, molecular inflammation, and bedside decisions.
Gout is no longer just about pain control. It is about prevention, longevity, and systems level thinking.
Curious how others are integrating treat to target strategies into real world practice, and how we can do better for patients who are still being left behind.”
Title: Urate Lowering and Cardiovascular Risk—Extending the Benefits of a Treat-to-Target Strategy in Gout
Authors: Pascal Richette, Augustin Latourte, Hang-Korng Ea
Read the Full Article on JAMA Internal Medicine

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis
-
Nov 18, 2026, 20:55Nasir Jamal: Plasmapheresis – Key Concepts at a Glance
-
Nov 18, 2026, 20:55Tarık Seller: Pulmonary Embolism – When a Blood Clot Becomes a Life-Threatening Emergency
-
Nov 18, 2026, 20:53Sandya Arunachalam: Bringing the Profession Together at the Haemostasis and Thrombosis Workshop
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons